Obesity promotes liver carcinogenesis via Mcl-1 stabilization independent of IL-6Rα signaling

Cell Reports

Volumn 4, Issue 4, 2013, Pages 669-680

  Gruber, Sabine ^a   Straub, Beate K ^b   Ackermann, P Justus ^a   Wunderlich, Claudia M ^a   Mauer, Jan ^a   Seeger, Jens M ^c   Büning, Hildegard ^c   Heukamp, Lukas ^c   Kashkar, Hamid ^c   Schirmacher, Peter ^b   Brüning, Jens C ^a   Wunderlich, F Thomas ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^c UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DIETHYLNITROSAMINE; GLYCOGEN SYNTHASE KINASE 3BETA; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR ALPHA; PHOSPHOPROTEIN PHOSPHATASE 1; PHOSPHOPROTEIN PHOSPHATASE 1 ALPHA; PROTEIN MCL 1; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; ENZYME INACTIVATION; LIVER CARCINOGENESIS; LIVER CELL; LIVER CELL CARCINOMA; MALE; MOUSE; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN EXPRESSION; PROTEIN METABOLISM; PROTEIN STABILITY; SIGNAL TRANSDUCTION;

ANIMALS; APOPTOSIS; CARCINOGENESIS; GLYCOGEN SYNTHASE KINASE 3; HEP G2 CELLS; HEPATOCYTES; HUMANS; LIVER NEOPLASMS, EXPERIMENTAL; MICE; MICE, KNOCKOUT; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; OBESITY; PROTEIN PHOSPHATASE 1; PROTEIN STABILITY; RECEPTORS, INTERLEUKIN-6; SIGNAL TRANSDUCTION; UBIQUITIN-PROTEIN LIGASES;

EID: 84883280808     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2013.07.023     Document Type: Article

References (44)

1. Bianchini F., Kaaks R., Vainio H. Overweight, obesity, and cancer risk. Lancet Oncol. 2002, 3:565-574.
2. Bisgaard H.C., Thorgeirsson S.S. Hepatic regeneration. The role of regeneration in pathogenesis of chronic liver diseases. Clin. Lab. Med. 1996, 16:325-339.
3. Brunelle J.K., Letai A. Control of mitochondrial apoptosis by the Bcl-2 family. J.Cell Sci. 2009, 122:437-441.
4. Calle E.E., Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat. Rev. Cancer 2004, 4:579-591.
5. Calle E.E., Rodriguez C., Walker-Thurmond K., Thun M.J. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N.Engl. J. Med. 2003, 348:1625-1638.
6. Charvet C., Wissler M., Brauns-Schubert P., Wang S.J., Tang Y., Sigloch F.C., Mellert H., Brandenburg M., Lindner S.E., Breit B., et al. Phosphorylation of Tip60 by GSK-3 determines the induction of PUMA and apoptosis by p53. Mol. Cell 2011, 42:584-596.
7. Cross D.A., Alessi D.R., Cohen P., Andjelkovich M., Hemmings B.A. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 1995, 378:785-789.
8. Ding Q., He X., Hsu J.M., Xia W., Chen C.T., Li L.Y., Lee D.F., Liu J.C., Zhong Q., Wang X., Hung M.C. Degradation of Mcl-1 by beta-TrCP mediates glycogen synthase kinase 3-induced tumor suppression and chemosensitization. Mol. Cell. Biol. 2007, 27:4006-4017.
9. Domina A.M., Vrana J.A., Gregory M.A., Hann S.R., Craig R.W. MCL1 is phosphorylated in the PEST region and stabilized upon ERK activation in viable cells, and at additional sites with cytotoxic okadaic acid or taxol. Oncogene 2004, 23:5301-5315.
10. Eldar-Finkelman H., Krebs E.G. Phosphorylation of insulin receptor substrate 1 by glycogen synthase kinase 3 impairs insulin action. Proc. Natl. Acad. Sci. USA 1997, 94:9660-9664.
11. Eldar-Finkelman H., Schreyer S.A., Shinohara M.M., LeBoeuf R.C., Krebs E.G. Increased glycogen synthase kinase-3 activity in diabetes- and obesity-prone C57BL/6J mice. Diabetes 1999, 48:1662-1666.
12. Epling-Burnette P.K., Liu J.H., Catlett-Falcone R., Turkson J., Oshiro M., Kothapalli R., Li Y., Wang J.M., Yang-Yen H.F., Karras J., et al. Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. J.Clin. Invest. 2001, 107:351-362.
13. Fang X., Yu S.X., Lu Y., Bast R.C., Woodgett J.R., Mills G.B. Phosphorylation and inactivation of glycogen synthase kinase 3 by protein kinase A. Proc. Natl. Acad. Sci. USA 2000, 97:11960-11965.
14. Fang X., Yu S., Tanyi J.L., Lu Y., Woodgett J.R., Mills G.B. Convergence of multiple signaling cascades at glycogen synthase kinase 3: Edg receptor-mediated phosphorylation and inactivation by lysophosphatidic acid through a protein kinase C-dependent intracellular pathway. Mol. Cell. Biol. 2002, 22:2099-2110.
15. Fleischer B., Schulze-Bergkamen H., Schuchmann M., Weber A., Biesterfeld S., Müller M., Krammer P.H., Galle P.R. Mcl-1 is an anti-apoptotic factor for human hepatocellular carcinoma. Int. J. Oncol. 2006, 28:25-32.
16. Ford E.S., Mokdad A.H. Epidemiology of obesity in the Western Hemisphere. J.Clin. Endocrinol. Metab. 2008, 93(11, Suppl 1):S1-S8.
17. Hanger D.P., Hughes K., Woodgett J.R., Brion J.P., Anderton B.H. Glycogen synthase kinase-3 induces Alzheimer's disease-like phosphorylation of tau: generation of paired helical filament epitopes and neuronal localisation of the kinase. Neurosci. Lett. 1992, 147:58-62.
18. Heinrich P.C., Behrmann I., Haan S., Hermanns H.M., Müller-Newen G., Schaper F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem. J. 2003, 374:1-20.
19. Hikita H., Kodama T., Shimizu S., Li W., Shigekawa M., Tanaka S., Hosui A., Miyagi T., Tatsumi T., Kanto T., et al. Bak deficiency inhibits livercarcinogenesis: a causal link between apoptosis and carcinogenesis. J.Hepatol. 2012, 57:92-100.
20. Hirosumi J., Tuncman G., Chang L., Görgün C.Z., Uysal K.T., Maeda K., Karin M., Hotamisligil G.S. A central role for JNK in obesity and insulin resistance. Nature 2002, 420:333-336.
21. Hotamisligil G.S. Inflammation and metabolic disorders. Nature 2006, 444:860-867.
22. Hui L., Zatloukal K., Scheuch H., Stepniak E., Wagner E.F. Proliferation of human HCC cells and chemically induced mouse liver cancers requires JNK1-dependent p21 downregulation. J.Clin. Invest. 2008, 118:3943-3953.
23. Jourdan M., Veyrune J.L., De Vos J., Redal N., Couderc G., Klein B. A major role for Mcl-1 antiapoptotic protein in the IL-6-induced survival of human myeloma cells. Oncogene 2003, 22:2950-2959.
24. Kodama Y., Taura K., Miura K., Schnabl B., Osawa Y., Brenner D.A. Antiapoptotic effect of c-Jun N-terminal Kinase-1 through Mcl-1 stabilization in TNF-induced hepatocyte apoptosis. Gastroenterology 2009, 136:1423-1434.
25. Kozopas K.M., Yang T., Buchan H.L., Zhou P., Craig R.W. MCL1, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to BCL2. Proc. Natl. Acad. Sci. USA 1993, 90:3516-3520.
26. Luedde T., Beraza N., Kotsikoris V., van Loo G., Nenci A., De Vos R., Roskams T., Trautwein C., Pasparakis M. Deletion of NEMO/IKKgamma in liver parenchymal cells causes steatohepatitis and hepatocellular carcinoma. Cancer Cell 2007, 11:119-132.
27. Maurer U., Charvet C., Wagman A.S., Dejardin E., Green D.R. Glycogen synthase kinase-3 regulates mitochondrial outer membrane permeabilization and apoptosis by destabilization of MCL-1. Mol. Cell 2006, 21:749-760.
28. McFarland-Mancini M.M., Funk H.M., Paluch A.M., Zhou M., Giridhar P.V., Mercer C.A., Kozma S.C., Drew A.F. Differences in wound healing in mice with deficiency of IL-6 versus IL-6 receptor. J.Immunol. 2010, 184:7219-7228.
29. Morel C., Carlson S.M., White F.M., Davis R.J. Mcl-1 integrates the opposing actions of signaling pathways that mediate survival and apoptosis. Mol. Cell. Biol. 2009, 29:3845-3852.
30. Naugler W.E., Sakurai T., Kim S., Maeda S., Kim K., Elsharkawy A.M., Karin M. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science 2007, 317:121-124.
31. Nishimura S., Manabe I., Nagasaki M., Eto K., Yamashita H., Ohsugi M., Otsu M., Hara K., Ueki K., Sugiura S., et al. CD8+ effector Tcells contribute to macrophage recruitment and adipose tissue inflammation in obesity. Nat. Med. 2009, 15:914-920.
32. Park E.J., Lee J.H., Yu G.Y., He G., Ali S.R., Holzer R.G., Osterreicher C.H., Takahashi H., Karin M. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell 2010, 140:197-208.
33. Patel S., Woodgett J. Glycogen synthase kinase-3 and cancer: good cop, bad cop?. Cancer Cell 2008, 14:351-353.
34. Schulze-Bergkamen H., Fleischer B., Schuchmann M., Weber A., Weinmann A., Krammer P.H., Galle P.R. Suppression of Mcl-1 via RNA interference sensitizes human hepatocellular carcinoma cells towards apoptosis induction. BMC Cancer 2006, 6:232.
35. Vick B., Weber A., Urbanik T., Maass T., Teufel A., Krammer P.H., Opferman J.T., Schuchmann M., Galle P.R., Schulze-Bergkamen H. Knockout of myeloid cell leukemia-1 induces liver damage and increases apoptosis susceptibility of murine hepatocytes. Hepatology 2009, 49:627-636.
36. Wang Q.M., Fiol C.J., DePaoli-Roach A.A., Roach P.J. Glycogen synthase kinase-3 beta is a dual specificity kinase differentially regulated by tyrosine and serine/threonine phosphorylation. J.Biol. Chem. 1994, 269:14566-14574.
37. Wang J.M., Chao J.R., Chen W., Kuo M.L., Yen J.J., Yang-Yen H.F. The antiapoptotic gene mcl-1 is up-regulated by the phosphatidylinositol 3-kinase/Akt signaling pathway through a transcription factor complex containing CREB. Mol. Cell. Biol. 1999, 19:6195-6206.
38. Weber A., Boger R., Vick B., Urbanik T., Haybaeck J., Zoller S., Teufel A., Krammer P.H., Opferman J.T., Galle P.R., et al. Hepatocyte-specific deletion of the antiapoptotic protein myeloid cell leukemia-1 triggers proliferation and hepatocarcinogenesis in mice. Hepatology 2010, 51:1226-1236.
39. Wertz I.E., Kusam S., Lam C., Okamoto T., Sandoval W., Anderson D.J., Helgason E., Ernst J.A., Eby M., Liu J., et al. Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7. Nature 2011, 471:110-114.
40. Wunderlich F.T., Luedde T., Singer S., Schmidt-Supprian M., Baumgartl J., Schirmacher P., Pasparakis M., Brüning J.C. Hepatic NF-kappa B essential modulator deficiency prevents obesity-induced insulin resistance but synergizes with high-fat feeding in tumorigenesis. Proc. Natl. Acad. Sci. USA 2008, 105:1297-1302.
41. Wunderlich F.T., Ströhle P., Könner A.C., Gruber S., Tovar S., Brönneke H.S., Juntti-Berggren L., Li L.S., van Rooijen N., Libert C., et al. Interleukin-6 signaling in liver-parenchymal cells suppresses hepatic inflammation and improves systemic insulin action. Cell Metab. 2010, 12:237-249.
42. Wunderlich C.M., Delic D., Behnke K., Meryk A., Strohle P., Chaurasia B., Al-Quraishy S., Wunderlich F., Bruning J.C., Wunderlich F.T. Cutting edge: Inhibition of IL-6 trans-signaling protects from malaria-induced lethality in mice. J Immunol 2012, 188:4141-4144.
43. Xu H., Barnes G.T., Yang Q., Tan G., Yang D., Chou C.J., Sole J., Nichols A., Ross J.S., Tartaglia L.A., Chen H. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J.Clin. Invest. 2003, 112:1821-1830.
44. Zhong Q., Gao W., Du F., Wang X. Mule/ARF-BP1, a BH3-only E3 ubiquitin ligase, catalyzes the polyubiquitination of Mcl-1 and regulates apoptosis. Cell 2005, 121:1085-1095.